期刊文献+
共找到198篇文章
< 1 2 10 >
每页显示 20 50 100
Prostatic Adenomectomy and Comorbidities: Frequency and Management at the Urology Department of the Ignace Deen National Hospital in Conakry
1
作者 Demba Cisse Alpha Oumar Barry +9 位作者 Morlaye Fatoumata Bangoura Alimou Diallo Mamadou Dian Bah Youssouf Keita Daouda Kanté Thierno Mamadou Oury Diallo Mamadou Bissiriou Bah Mamadou Diawo Bah Abdoulaye Bobo Diallo Oumar Raphiou Bah 《Open Journal of Urology》 2024年第4期217-226,共10页
Goal: To determine the type of comorbidity and highlight the complications of adenomectomy and comorbidities. Material and Methods: This is a prospective, descriptive, cross-sectional study lasting six (6) months, fro... Goal: To determine the type of comorbidity and highlight the complications of adenomectomy and comorbidities. Material and Methods: This is a prospective, descriptive, cross-sectional study lasting six (6) months, from July 1, 2022 to December 31, 2022. Patients with BPH on comorbidity condition taken care of during the study period AND have agreed to participate in the study. Results: During our study, 49 cases of benign prostatic hypertrophy with comorbidities were collected, representing a frequency of 29%. The average age ranges for the patients were 43 - 70 years. The age group most affected was 70 to 79 years old (38.80%). Nocturnal urinary frequency was the main reason for consultation present in all our patients. The most frequent comorbidity was hypertension, i.e. 83.70%. The PSA rate between 4 and 10 was the most represented, i.e. 42.86%. The prostate volume was between 61 and 100 ml in 40.82% of patients. Histology showed that it was a benign adenomatous hypertrophy of the prostate in 85.70% and a prostatic adenomyoma in 14.29%. Trans-bladder adenomectomy alone was the most performed technique, i.e. 49%, followed by trans urethral resection of the prostate, i.e. 38.80%. Retention of urine after removal of the catheter was the most observed complication, i.e. 12.20%. Conclusion: Benign prostatic hypertrophy with comorbidities constitutes a frequent association. Because their presence can affect effectiveness and lead to complications. 展开更多
关键词 Prostatic Hypertrophy comorbidities Conakry University Hospital
下载PDF
Tuberculosis-diabetes comorbidities: Mechanistic insights for clinical considerations and treatment challenges
2
作者 Md Abdul Alim Al-Bari Nicholas Peake Nabil Eid 《World Journal of Diabetes》 SCIE 2024年第5期853-866,共14页
Tuberculosis(TB)remains a leading cause of death among infectious diseases,particularly in poor countries.Viral infections,multidrug-resistant and ex-tensively drug-resistant TB strains,as well as the coexistence of c... Tuberculosis(TB)remains a leading cause of death among infectious diseases,particularly in poor countries.Viral infections,multidrug-resistant and ex-tensively drug-resistant TB strains,as well as the coexistence of chronic illnesses such as diabetes mellitus(DM)greatly aggravate TB morbidity and mortality.DM[particularly type 2 DM(T2DM)]and TB have converged making their control even more challenging.Two contemporary global epidemics,TB-DM behaves like a syndemic,a synergistic confluence of two highly prevalent diseases.T2DM is a risk factor for developing more severe forms of multi-drug resistant-TB and TB recurrence after preventive treatment.Since a bidirectional relationship exists between TB and DM,it is necessary to concurrently treat both,and promote recommendations for the joint management of both diseases.There are also some drug-drug interactions resulting in adverse treatment outcomes in TB-DM patients including treatment failure,and reinfection.In addition,autophagy may play a role in these comorbidities.Therefore,the TB-DM comorbidities present several health challenges,requiring a focus on multidisciplinary collaboration and integrated strategies,to effectively deal with this double burden.To effectively manage the comorbidity,further screening in affected countries,more suitable drugs,and better treatment strategies are required. 展开更多
关键词 Diabetes mellitus TUBERCULOSIS Coinfections COMORBIDITY Drug-drug interactions Autophagy Treatment challenges
下载PDF
Incidence,prevalence,and comorbidities of chronic pancreatitis:A 7-year population-based study 被引量:1
3
作者 Qiu-Yu Cai Kun Tan +5 位作者 Xue-Li Zhang Xu Han Jing-Ping Pan Zhi-Yin Huang Cheng-Wei Tang Jing Li 《World Journal of Gastroenterology》 SCIE CAS 2023年第30期4671-4684,共14页
BACKGROUND Chronic pancreatitis(CP)is a fibroinflammatory syndrome leading to reduced quality of life and shortened life expectancy.Population-based estimates of the incidence,prevalence,and comorbidities of CP in Chi... BACKGROUND Chronic pancreatitis(CP)is a fibroinflammatory syndrome leading to reduced quality of life and shortened life expectancy.Population-based estimates of the incidence,prevalence,and comorbidities of CP in China are scarce.AIM To characterize the incidence,prevalence,and comorbidities of CP in Sichuan Province,China,with population-based data.METHODS Data on CP from 2015 to 2021 were obtained from the Health Information Center of Sichuan Province.During the study period,a total of 38090 individuals were diagnosed with CP in Sichuan Province.The yearly incidence rate and point prevalence rate(December 31,2021)of CP were calculated.The prevalence of comorbid conditions in CP patients was estimated.The annual number of CPrelated hospitalizations,hospital length of stay,and hospitalization costs for CP were evaluated.Yearly incidence rates were standardized for age by the direct method using the permanent population of Sichuan Province in the 2020 census as the standard population.An analysis of variance test for the linearity of scaled variables and the Cochran-Armitage trend test for categorical data were performed to investigate the yearly trends,and a two-sided test with P<0.05 was considered statistically significant.RESULTS The 38090 CP patients comprised 23280 males and 14810 females.The mean age of patients at CP diagnosis was 57.83 years,with male patients(55.87 years)being younger than female patients(60.11 years)(P<0.001).The mean incidence rate of CP during the study period was 6.81 per 100000 person-years,and the incidence of CP increased each year,from 4.03 per 100000 person-years in 2015 to 8.27 per 100000 person-years in 2021(P<0.001).The point prevalence rate of CP in 2021 was 45.52 per 100000 individuals for the total population,with rates of 55.04 per 100000 individuals for men and 35.78 per 100000 individuals for women(P<0.001).Individuals aged 65 years or older had the highest prevalence of CP(113.38 per 100000 individuals)(P<0.001).Diabetes(26.32%)was the most common comorbidity in CP patients.The number of CP-related hospitalizations increased from 3739 in 2015 to 11009 in 2021.The total costs for CP-related hospitalizations for CP patients over the study period were 667.96 million yuan,with an average of 17538 yuan per patient.CONCLUSION The yearly incidence of CP is increasing,and the overall CP hospitalization cost has increased by 1.4 times during the last 7 years,indicating that CP remains a heavy health burden. 展开更多
关键词 Chronic pancreatitis EPIDEMIOLOGY INCIDENCE PREVALENCE comorbidities Disease burden
下载PDF
Ten-year multicentric retrospective analysis regarding postoperative complications and impact of comorbidities in hemorrhoidal surgery with literature review
4
作者 Cosmin Moldovan Elena Rusu +8 位作者 Daniel Cochior Madalina Elena Toba Horia Mocanu Razvan Adam Mirela Rimbu Adrian Ghenea Florin Savulescu Daniela Godoroja Florin Botea 《World Journal of Clinical Cases》 SCIE 2023年第2期366-384,共19页
BACKGROUND Hemorrhoidal disease(HD)is considered a low-severity pathology by both general population and physicians,but the lengthy conservative therapy and postoperative complications suggest otherwise.AIM To assess ... BACKGROUND Hemorrhoidal disease(HD)is considered a low-severity pathology by both general population and physicians,but the lengthy conservative therapy and postoperative complications suggest otherwise.AIM To assess the effectiveness of different treatment options,both conservative and surgical,in contrast with some preexisting comorbidities.METHODS We conducted a retrospective,10-yearlong study between January 2011 and December 2021 in two surgical centers,a private and a state-owned hospital.We compared the efficacy and safety of several treatment options,such as open hemorrhoidectomy,stapled hemorrhoidopexy,rubber band ligation and infrared coagulation in terms of complication rates and types and their correlation with different preexisting comorbidities such as inflammatory bowel disease(IBD),use of anticoagulant medication(AM)and liver cirrhosis.We also conducted a 20-years long PubMed research(1.263 articles)for relevant comparisons.RESULTS Our study recorded 10940 patients with HD,10241 with conservative and 699 with surgical treatment.Out of these,the male-to-female ratio of 1.3,and a peak in age distribution between 59 and 68 years old(32%of patients).For the entire study,we recorded a 90%incidence of immediate pain,immediate bleeding in 1.5%(11 cases),delayed bleeding in 1.0%(7 cases),and 0.6%surgical site infections.Urinary retention was also present,with 0.2%of patients,anal stricture in 1%and fecal incontinence for 0.5%of patients(4 cases).We recorded no severe complications such as Fournier`s gangrene or rectovaginal perforations.IBD accounted for 6%of the patients,with ulcerative colitis in 12%and Chron`s disease in 10.5%.6.6%of the patients had AM,determining 4%immediate and 2%delayed bleeding,in surgically treated patients.CONCLUSION Our study determined that most common complications(pain,urinary retention,bleeding,and stricture)are correlated with each surgical technique and pre-existing comorbidities. 展开更多
关键词 RETROSPECTIVE Hemorrhoidal POSTOPERATIVE COMPLICATIONS comorbidities
下载PDF
Age,blood tests and comorbidities and AIMS65 risk scores outperform Glasgow-Blatchford and pre-endoscopic Rockall score in patients with upper gastrointestinal bleeding
5
作者 Bianca Codrina Morarasu Victorita Sorodoc +9 位作者 Anca Haisan Stefan Morarasu Cristina Bologa Raluca Ecaterina Haliga Catalina Lionte Emilia Adriana Marciuc Mohammed Elsiddig Diana Cimpoesu Gabriel Mihail Dimofte Laurentiu Sorodoc 《World Journal of Clinical Cases》 SCIE 2023年第19期4513-4530,共18页
BACKGROUND Upper gastrointestinal(GI)bleeding is a life-threatening condition with high mortality rates.AIM To compare the performance of pre-endoscopic risk scores in predicting the following primary outcomes:In-hosp... BACKGROUND Upper gastrointestinal(GI)bleeding is a life-threatening condition with high mortality rates.AIM To compare the performance of pre-endoscopic risk scores in predicting the following primary outcomes:In-hospital mortality,intervention(endoscopic or surgical)and length of admission(≥7 d).METHODS We performed a retrospective analysis of 363 patients presenting with upper GI bleeding from December 2020 to January 2021.We calculated and compared the area under the receiver operating characteristics curves(AUROCs)of Glasgow-Blatchford score(GBS),pre-endoscopic Rockall score(PERS),albumin,international normalized ratio,altered mental status,systolic blood pressure,age older than 65(AIMS65)and age,blood tests and comorbidities(ABC),including their optimal cut-off in variceal and non-variceal upper GI bleeding cohorts.We subsequently analyzed through a logistic binary regression model,if addition of lactate increased the score performance.RESULTS All scores had discriminative ability in predicting in-hospital mortality irrespective of study group.AIMS65 score had the best performance in the variceal bleeding group(AUROC=0.772;P<0.001),and ABC score(AUROC=0.775;P<0.001)in the non-variceal bleeding group.However,ABC score,at a cut-off value of 5.5,was the best predictor(AUROC=0.770,P=0.001)of inhospital mortality in both populations.PERS score was a good predictor for endoscopic treatment(AUC=0.604;P=0.046)in the variceal population,while GBS score,(AUROC=0.722;P=0.024),outperformed the other scores in predicting surgical intervention.Addition of lactate to AIMS65 score,increases by 5-fold the probability of in-hospital mortality(P<0.05)and by 12-fold if added to GBS score(P<0.003).No score proved to be a good predictor for length of admission.CONCLUSION ABC score is the most accurate in predicting in-hospital mortality in both mixed and non-variceal bleeding population.PERS and GBS should be used to determine need for endoscopic and surgical intervention,respectively.Lactate can be used as an additional tool to risk scores for predicting inhospital mortality. 展开更多
关键词 Glasgow-Blatchford Pre-endoscopic Rockall Age older than 65 Age blood tests and comorbidities Risk score Gastrointestinal bleeding
下载PDF
Research on Effects of Comorbidities Disease on Anticoagulation and Bleeding Disorders Risk in Patients with Overdosage of Vitamin K Antagonist Anticoagulant
6
作者 Si Dung Chu Minh Thi Tran 《Open Journal of Emergency Medicine》 2023年第3期68-79,共12页
Objectives: Research on effects of comorbidities disease on anticoagulation overdose in patients receiving anticoagulant therapy with vitamin K antagonists anticoagulant (VKAs) drugs at HaiPhong-VinhBao International ... Objectives: Research on effects of comorbidities disease on anticoagulation overdose in patients receiving anticoagulant therapy with vitamin K antagonists anticoagulant (VKAs) drugs at HaiPhong-VinhBao International General Hospital. Methods: Description and Prospective study. Research on 79 patients receiving anticoagulant therapy with VKAs who have an INR testing index of more than anticoagulation dose with VKAs and check INR every 4 weeks. Results: The average research age is 65.65 ± 12.17 years [33: 85], most of the elderly group. The Male group is lower than the female group (p > 0.05). Patients with hemorrhage signs account for 22.8%. The INR testing index has an average value is 5.88 ± 3.0 [3.02 - 23.95];The group of INR > 5 level is a higher risk of bleeding than the group of INR ≤ 5 levels, there is statistical difference (p Conclusion: All most patients with anticoagulation overdose are in the elderly group. The group with INR > 5 levels has a higher risk of bleeding than the group with INR ≤ 5 levels, it’s the statistical significance (p 1 but p > 0.05);Patients used VKAs drugs on the background of kidney failure or arthritis pathology are the cause of the increased risk of bleeding, it’s statistical significance (p < 0.05). 展开更多
关键词 comorbidities Disease INR VKAs Bleeding Disorders
下载PDF
An overview of the mechanism of acupuncture and moxibustion in treating depression comorbidities insomnia
7
作者 WANG Tian SU Sheng-yong +5 位作者 ZHANG Xi LIN Xin-ying WANG Qiong-xiao SU Ting XIE Cai-yun HUANG Lin 《Journal of Hainan Medical University》 CAS 2023年第15期55-59,共5页
Depression and insomnia have become a frequent disease in the clinic.Clinically,depression and insomnia occur synchronously.Most researchers believe acupuncture treats insomnia and depression comorbidity through mecha... Depression and insomnia have become a frequent disease in the clinic.Clinically,depression and insomnia occur synchronously.Most researchers believe acupuncture treats insomnia and depression comorbidity through mechanisms such as inflammation theory,HPA axis theory,neurotransmitter theory,nervous system structure theory,immunoregulation theory,etc.Acupuncture has a clear effect on depression and insomnia comorbidity,and is two-way,specific,and integral.Therefore,a summary on the mechanism of using acupuncture to treat depression and insomnia comorbidity is made,to provide reference for future clinical application and laboratory research. 展开更多
关键词 Depression comorbidity insomnia Acupuncture Mechanism research Review
下载PDF
Prevalence of Comorbidities in the Urological Patients at the Former Military Teaching Hospital of Cotonou
8
作者 Sossa Jean Fanou Lionelle +3 位作者 Hounto Yao Félicien Yevi Dodji Magloire Inès Hodonou Fred Martin Avakoudjo Déjinnin Josué Georges 《Open Journal of Urology》 2023年第11期476-483,共8页
Background: Comorbidities are additive diseases and care burdens in urological patients. Determining the epidemiologic profile of comorbidities in urological patients in our setting may help us to better the managemen... Background: Comorbidities are additive diseases and care burdens in urological patients. Determining the epidemiologic profile of comorbidities in urological patients in our setting may help us to better the management of urological disease. Objective: To evaluate the prevalence of comorbidities in urological patients. Patient and Method: We collected comorbidity, urological disease and demographic data in all urological patients managed at the former Military Teaching Hospital of Cotonou from January 1, 2012, to December 31, 2020. We used the software R 4.2.2 to perform descriptive and bi-varied data analysis. Student’s t test was used to compare means. Results: The prevalence of comorbidities was 14.2%, i.e., 601 comorbidity-affected among 4242 patients. The comorbidities predominantly affected men: the sex ratio was 13:1. The presence of comorbidity was correlated with patients’ age (p < 0.001). The comorbidities observed in the 601 affected patients were hypertension (84.5%), diabetes (26.5%), asthma (2%), and heart failure (1.2%). Hypertension (p = 0.001) and asthma (p = 0.030) were correlated with age. No comorbidity was associated with gender. The comorbidities’ prevalence was highest in patients aged 40 - 80 years who presented urological diseases such as BPH (68.9%), Erectile dysfunction (ED) and ejaculatory disorders, overactive bladder (OAB) and neurogenic lower urinary tract dysfunction (LUTD), renal cyst (5%), inguinal hernia (4.2%), urinary stones (2.8%), and prostate cancer (2.3%). Conclusion: The comorbidities’ prevalence was 14.2% in the urological patients. The main comorbidities were hypertension (84.5%) and diabetes mellitus (26.5%). 展开更多
关键词 COMORBIDITY Urological Patients PREVALENCE
下载PDF
Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China 被引量:8
9
作者 MA Yan ZHU Dong Shan +62 位作者 CHEN Ren Bo SHI Nan Nan LIU Si Hong FAN Yi Pin WU Gui Hui YANG Pu Ye BAI Jiang Feng CHEN Hong CHEN Li Ying FENG Qiao GUO Tuan Mao HOU Yong HU Gui Fen HU Xiao Mei HU Yun Hong HUANG Jin HUANG Qiu Hua HUANG Shao Zhen JI Liang JIN Hai Hao LEI Xiao LI Chun Yan LI Min Qing LI Qun Tang LI Xian Yong LIU Hong De LIU Jin Ping LIU Zhang MA Yu Ting MAO Ya MO Liu Fen NA Hui WANG Jing Wei SONG Fang Li SUN Sheng WANG Dong Ting WANG Ming Xuan WANG Xiao Yan WANG Yin Zhen WANG Yu Dong WU Wei WU Lan Ping XIAO Yan Hua XIE Hai Jun XU Hong Ming XU Shou Fang XUE Rui Xia YANG Chun YANG Kai Jun YUAN Sheng Li ZHANG Gong Qi ZHANG Jin Bo ZHANG Lin Song ZHAO Shu Sen ZHAO Wan Ying ZHENG Kai ZHOU Ying Chun ZHU Jun Teng ZHU Tian Qing ZHANG Hua Min WANG Yan Ping WANG Yong Yan 《Biomedical and Environmental Sciences》 SCIE CAS CSCD 2020年第12期893-905,共13页
Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the ris... Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains unclear.Methods A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients’ medical records. Multivariable logistic regression models were used to estimate the odds ratio(OR) and 95% confidence interval(95% CI) of the associations between comorbidities(cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of COVID-19.Results Overall, 158(13.6%) patients were diagnosed with severe illness and 32(2.7%) had unfavorable outcomes. Hypertension(2.87, 1.30–6.32), type 2 diabetes(T2 DM)(3.57, 2.32–5.49),cardiovascular disease(CVD)(3.78, 1.81–7.89), fatty liver disease(7.53, 1.96–28.96), hyperlipidemia(2.15, 1.26–3.67), other lung diseases(6.00, 3.01–11.96), and electrolyte imbalance(10.40, 3.00–26.10)were independently linked to increased odds of being severely ill. T2 DM(6.07, 2.89–12.75), CVD(8.47,6.03–11.89), and electrolyte imbalance(19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission(5.46,3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes(6.58, 1.46–29.64) within two weeks.Conclusion Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes. 展开更多
关键词 comorbidities COVID-19 SEVERITY GENDER Age Treatment outcome
下载PDF
Association of comorbidities with increasing severity of peripheral neuropathy in diabetes mellitus 被引量:7
10
作者 Shafna Sachedina Cory Toth 《World Journal of Diabetes》 SCIE CAS 2013年第4期135-144,共10页
AIM: To analyze a large population of patients with diabetes and peripheral neuropathy(PN) to determine other meaningful comorbid etiologies for PN.METHODS: Peripheral Neuropathy is a common complication of type 1 and... AIM: To analyze a large population of patients with diabetes and peripheral neuropathy(PN) to determine other meaningful comorbid etiologies for PN.METHODS: Peripheral Neuropathy is a common complication of type 1 and 2 diabetes mellitus;however,other potential causes for PN may be co-existing in patients with diabetes.A prospective cohort study was performed to assess patients with diabetes and PN.We compared patients having PN due solely to diabetes with patients possessing co-existing comorbidities,performing clinical(Toronto Clinical Scoring System and the Utah Early Neuropathy Scale),laboratory and electrophysiological assessments in all patients.RESULTS: Patients with either type 1 or 2 diabetes mellitus and co-existing comorbidities did not have more severe clinical or electrophysiological PN phenotypes overall.However,in patients with type 1 diabetes,presence of a lipid disorder was associated with greater PN severity.In type 2 diabetes patients,both a lipid disorder and cobalamin deficiency were associated with greater PN severity.There was no additive effect upon PN severity with presence of three or more comorbid etiologies.CONCLUSION: The presence of specific,and not general,comorbidities in patients with type 1 or 2 diabetes corresponds with greater PN severity. 展开更多
关键词 DIABETIC peripheral NEUROPATHY comorbidities Lipidemia COBALAMIN Methylmalonic acid
下载PDF
Comparative profile for COVID-19 cases from China and North America: Clinical symptoms, comorbidities and disease biomarkers 被引量:1
11
作者 Alaa Badawi Denitsa Vasileva 《World Journal of Clinical Cases》 SCIE 2021年第1期118-132,共15页
BACKGROUND Large inter-individual and inter-population differences in the susceptibility to and outcome of severe acute respiratory syndrome coronavirus 2 or coronavirus disease 2019(COVID-19)have been noted.Understan... BACKGROUND Large inter-individual and inter-population differences in the susceptibility to and outcome of severe acute respiratory syndrome coronavirus 2 or coronavirus disease 2019(COVID-19)have been noted.Understanding these differences and how they influence vulnerability to infection and disease severity is critical to public health intervention.AIM To analyze and compare the profile of COVID-19 cases between China and North America as two regions that differ in many environmental,host and healthcare factors related to disease risk.METHODS We conducted a meta-analysis to examine and compare demographic information,clinical symptoms,comorbidities,disease severity and levels of disease biomarkers of COVID-19 cases from clinical studies and data from China(105 studies)and North America(19 studies).RESULTS COVID-19 patients from North America were older than their Chinese counterparts and with higher male:Female ratio.Fever,cough,fatigue and dyspnea were the most common clinical symptoms in both study regions(present in about 30%to 75%of the cases in both regions).Meta-analysis for the prevalence of comorbidities(such as obesity,hypertension,diabetes,cardiovascular diseases,chronic obstructive pulmonary disease,cancer,and chronic kidney diseases)in COVID-19 patients were all significantly more prevalent in North America compared to China.Comorbidities were positively correlated with age but at a significantly younger age range in China compared to North American.The most prevalent infection outcome was acute respiratory distress syndrome which was 2-fold more frequent in North America than in China.Levels of C-reactive protein were 4.5-fold higher in the North American cases than in cases from China.CONCLUSION The differences in the profile of COVID-19 cases from China and North America may relate to differences in environmental-,host-and healthcare-related factors between the two regions.Such inter-population differences-together with intrapopulation variability-underline the need to characterize the effect of health inequities and inequalities on public health response to COVID-19 and can assist in preparing for the re-emergence of the epidemic. 展开更多
关键词 COVID-19 SYMPTOMS comorbidities China North America ADULTS
下载PDF
Survival and comorbidities in lung cancer patients:Evidence from administrative claims data in Germany 被引量:1
12
作者 DIEGO HERNANDEZ CHIH-YUAN CHENG +1 位作者 KARLA HERNANDEZ-VILLAFUERTE MICHAEL SCHLANDER 《Oncology Research》 SCIE 2022年第4期173-185,共13页
Lung cancer is the most common cancer type worldwide and has the highest and second highest mortality rate for men and women respectively in Germany.Yet,the role of comorbid illnesses in lung cancer patient prognosis ... Lung cancer is the most common cancer type worldwide and has the highest and second highest mortality rate for men and women respectively in Germany.Yet,the role of comorbid illnesses in lung cancer patient prognosis is still debated.We analyzed administrative claims data from one of the largest statutory health insurance(SHI)funds in Germany,covering close to 9 million people(11%of the national population);observation period was from 2005 to 2019.Lung cancer patients and their concomitant diseases were identified by ICD-10-GM codes.Comorbidities were classified according to the Charlson Comorbidity Index(CCI).Incidence,comorbidity prevalence and survival are estimated considering sex,age at diagnosis,and place of residence.Kaplan Meier curves with 95%confidence intervals were built in relation to common comorbidities.We identified 70,698 lung cancer incident cases in the sample.Incidence and survival figures are comparable to official statistics in Germany.Most prevalent comorbidities are chronic obstructive pulmonary disease(COPD)(36.7%),followed by peripheral vascular disease(PVD)(18.7%),diabetes without chronic complications(17.4%),congestive heart failure(CHF)(16.5%)and renal disease(14.7%).Relative to overall survival,lung cancer patients with CHF,cerebrovascular disease(CEVD)and renal disease are associated with largest drops in survival probabilities(9%or higher),while those with PVD and diabetes without chronic complications with moderate drops(7%or lower).The study showed a negative association between survival and most common comorbidities among lung cancer patients,based on a large sample for Germany.Further research needs to explore the individual effect of comorbidities disentangled from that of other patient characteristics such as cancer stage and histology. 展开更多
关键词 Lung Cancer comorbidities SURVIVAL Administrative data Statutory health insurance
下载PDF
Regional disease characteristics and comorbidities of patients with schizophrenia in the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): Findings from an international large simple trial 被引量:1
13
作者 John M. Kane Wolfgang Fleischhacker +6 位作者 Francesca Kolitsopoulos Onur N. Karayal Jamie Geier Cynthia Siu Robert Reynolds Gerald Faich Brian L. Strom 《Open Journal of Psychiatry》 2012年第4期423-432,共10页
Background: Using baseline data from the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC), we assessed disease characteristics and prevalence of select comorbidities among subjects with schizophrenia in di... Background: Using baseline data from the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC), we assessed disease characteristics and prevalence of select comorbidities among subjects with schizophrenia in different clinical settings across 18 countries. ZODIAC was a randomized, open-label, one-year, large simple trial (LST) that enrolled 18,239 individuals with schizophrenia. Methods: Subjects were randomized to open-label treatment with ziprasidone (n = 9120) or olanzapine (n = 9119) in naturalistic (usual care) settings and followed for one year. Study sites (n = 749) applied minimal selection criteria in an attempt to make the study population as representative as possible of those receiving treatment in “real world” circumstances across the countries. Results: Mean patient age was 41 years, 55% were male, 34% were markedly ill or presented with more severe disease, and 66% of subjects had one or more select comorbid conditions [i.e. heart attack, stroke, hypertension, CAD/angina, high cholesterol/triglycerides, diabetes, or overweight (BMI ≥ 25)] at baseline. History of suicide attempt was greatest in the US (38%), compared with Sweden (34%), Brazil/South America (26%), Asia (23%), and Eastern Europe (20%). Overweight or obesity was the most prevalent comorbid risk factor, representing 60% of enrolled subjects, 70% of US subjects compared with 30% in Asia and 52% - 64% in the other regions studied. High cholesterol/triglycerides levels were found in 23% of US subjects compared with a relatively low prevalence in other countries (3% - 11%). History of cardiovascular or diabetes-related comorbidities was found in 31% of subjects. Current smoking (46.5%) and past smoking (11.8%) were common with men dominating the proportion of current smokers: US (61%);Asia (60%);Sweden (50%);Eastern Europe (49%);and Latin America (44%). Conclusions: Our findings indicate substantial baseline variations across countries in demographics, comorbid conditions, and psychiatric disease history. These data provide an international epidemiologic picture of schizophrenia and may help guide future research and treatment initiatives. 展开更多
关键词 LARGE SIMPLE TRIAL SCHIZOPHRENIA ZODIAC comorbidities
下载PDF
Extraskeletal symptoms and comorbidities of diffuse idiopathic skeletal hyperostosis
14
作者 Rabia Terzi 《World Journal of Clinical Cases》 SCIE 2014年第9期422-425,共4页
Diffuse idiopathic skeletal hyperostosis(DISH) is a noninflammatory disease characterized by calcification and ossification of soft tissues, mainly enthesis and spinal ligaments. The clinical presentation primarily in... Diffuse idiopathic skeletal hyperostosis(DISH) is a noninflammatory disease characterized by calcification and ossification of soft tissues, mainly enthesis and spinal ligaments. The clinical presentation primarily includes spinal involvement-induced pain and range of motion. Although rare, life-threatening gastrointestinal, respiratory or neurological events or severe morbidity due to bone compression on the adjacent structures may develop. There is a limited amount of data on DISHrelated events in the literature. In recent years, comorbid metabolic disorders are of great interest in patients with DISH. The early diagnosis of these conditions as well as rare entities allows an effective multidisciplinary approach for the treatment of DISH. In this article, we review extraskeletal symptoms and associated comorbidities in patients with DISH. 展开更多
关键词 Diffuse idiopathic skeletal hyperostosis SWALLOWING Respiratory symptoms Neurological symptoms comorbidities
下载PDF
Prevalence of Non-Communicable Diseases and Number of Comorbidities According to Differences in Household Income Levels in Japan: Analysis from National Health and Nutrition Survey
15
作者 Chika Horikawa Nobuko Murayama +5 位作者 Asami Ota Megumi Tsuruta Satoshi Matsunaga Kazuya Fujihara Osamu Hanyu Hirohito Sone 《Food and Nutrition Sciences》 2017年第1期19-30,共12页
Though it has been reported that in Western developed countries socioeconomic status is associated with non-communicable diseases (NCD), there are sparse evidence from Japan, midst an income gap that has been pointed ... Though it has been reported that in Western developed countries socioeconomic status is associated with non-communicable diseases (NCD), there are sparse evidence from Japan, midst an income gap that has been pointed out in recent years. Therefore, we examined the presence or absence of NCD and the number of comorbidities according to household income in Japanese, using data from the National Health and Nutrition Survey of 2010. 1287 men and 1659 women aged 20 - 79 years from households at 3 income levels (<2, 2 - 5.9, ≥6 million yen) were analyzed. Participants completed questionnaires regarding whether they had been diagnosed with NCD, as well as undergoing clinical laboratory tests. Logistic regression analyses were used for statistical analysis with adjustment for age, gender, household size, and population of municipalities. The prevalences of participants with high, medium, and low income were 22.3%, 57.6%, and 20.2%, respectively. Participants with the lowest income had the highest odds of hypertension (OR [95% confidence interval (CI)] = 1.71 [1.29 - 2.26], p p = 0.041), and stroke (5.07 [2.04 - 12.60] p < 0.001). Additionally, prevalences of participants with 2 or 3 NCD (hypertension, diabetes, and hypercholesterolemia) were 15.0% and 33.0% in high and low income levels, respectively. A low income could contribute to a high prevalence of NCD and large number of comorbidities among Japanese. Establishing a health policy in Japan is needed to enable an optimal health condition and lifestyle regardless of socioeconomic disparities. 展开更多
关键词 Non-Communicable Diseases comorbidities Household INCOME NATIONAL HEALTH and Nutrition Survey JAPAN
下载PDF
Targeting the Inflammation Culprit in Patients with Psoriasis/Psoriatic Arthritis and Associated Cardiovascular Comorbidities. Is the IL-17 Inhibitor the New Kid on the Block?
16
作者 Cornel Pater 《World Journal of Cardiovascular Diseases》 2019年第4期267-294,共28页
Despite half-century old, but comprehensive national and international guidance, evidence of clinical effectiveness and widespread agreement on management of risk factors along with sophisticated measures for primary ... Despite half-century old, but comprehensive national and international guidance, evidence of clinical effectiveness and widespread agreement on management of risk factors along with sophisticated measures for primary and secondary prevention of major cardiovascular events, cardiovascular disease remains the dominant cause of death and disability world-wide. Life style changes at population-level (e.g., lower salt and saturated fat consumption or reduced/banned amount of industrially-produced trans fatty acids in specific products, etc.) or changes at individual level (e.g., targeting modifiable risk factors/life style changes affecting smoking/tobacco use, poor diet, high blood cholesterol, high blood pressure, insufficient physical activity, overweight/obesity) have reduced coronary heart disease mortality to variable extent in different countries (mostly so reported in Finland, Iceland and Sweden) at the beginning of the new century. Overall, however, cardiovascular mortality is estimated to increase in the next coming years until 2030 at a cost exceeding US $1044 billion. Several decades of status quo are also noted in the therapeutic spectrum of cardiovascular disease, mainly consisting of variations to LDL-C lowering agents, antihypertensives, anticoagulants, antiplatelets and fibrinolytics. Most of the therapeutic interventions are “tertiary” in nature (probably some 60%), meaning that treatment is instituted once the individual has developed a pathologic condition;“secondary prevention” may cover some 25%?-?30% (meant to prevent re-occurrence of the condition or occurrence of complications) while “primary prevention” is left with 10%?-?15% share (most commonly implying life style changes at individual level and rarely pharmacological intervention). For almost three decades, the so-called inflammatory hypothesis has been promoted as a reasonable pathogenetic theory behind initiation and growth of atherosclerotic plaque (Alexander RW, 1994;Ross R, 1999). With the discovery of molecular and cellular pathways that promote atherosclerosis and the role of cytokines as inflammatory messengers, the concept as such—inflammation, has received a primordial role?in atherogenesis. The present review paper aims at ascertaining the role of inflammation as a common pathogenetic denominator of cardiovascular disease in patients primarily treated for their psoriasis and/or psoriatic arthritis. 展开更多
关键词 PSORIASIS Psoriatic Arthritis CARDIOVASCULAR comorbidities INFLAMMATION Cy-tokines IL-17
下载PDF
Association between Comorbidities and Selected Sociodemographic Factors with Complications of Diabetes: Results from the National Diabetic Registry Malaysia
17
作者 Nor Asiah Muhamad Mohd Hatta Abdul Mutalip +5 位作者 Normi Mustapha Nor Soleha Mohd Dali Tahir Aris Fatanah Ismail Shahnaz Murad Lokman Hakim Sulaiman 《Journal of Diabetes Mellitus》 2018年第3期84-97,共14页
Background: This study aims to determine the hazard ratio of having any complication from diabetes mellitus, and the associations between comorbidities and risk of having any complications from diabetes mellitus among... Background: This study aims to determine the hazard ratio of having any complication from diabetes mellitus, and the associations between comorbidities and risk of having any complications from diabetes mellitus among diabetic patients who have attended government primary care clinics. Methods: Secondary data were retrieved from the Malaysian National Diabetic Registry which included all patients who received care. The data from the study on the socio-demographic, diabetes complications, clinical and treatment characteristics were analyzed using descriptive statistics. Cox regression was performed to estimate the hazard ratio for comorbidities, tobacco use, duration of diabetes and socio-demography characteristics upon time to diabetic complications. Results: Adjusted for other covariates, increase number of comorbidities contributed the highest hazard ratio risk: 1 comorbid (aHR: 2.47, 95% CI: 2.39, 2.55), 2 comorbidities (aHR: 4.34, 95% CI: 4.22, 4.47), 3 comorbidities (aHR: 6.56, 95% CI: 6.31, 6.81) and 4 comorbidities (aHR: 9.13, 95% CI: 8.20, 10.17). Other factors: age > 40 years (8%) Malays (27%) and smokers (10%) have hazard risks to develop diabetic complications. Conclusions: Increase in number of comorbidities will increase the risk of getting diabetes complications. Other factors such as age, gender, race, smoking status and duration of diabetes are also noted to contribute to increase risk for diabetes complications. 展开更多
关键词 comorbidities COMPLICATIONS DIABETES Primary Care
下载PDF
Role of vitamin D deficiency and comorbidities in COVID-19
18
作者 Gabriela Gama Freire Alberca Ricardo Wesley Alberca 《World Journal of Virology》 2022年第1期85-89,共5页
Recent manuscripts described the incidence of vitamin D hypovitaminosis in coronavirus disease 2019(COVID-19)patients.Vitamin D deficiency is also common in patients with comorbidities that are associated with a poor ... Recent manuscripts described the incidence of vitamin D hypovitaminosis in coronavirus disease 2019(COVID-19)patients.Vitamin D deficiency is also common in patients with comorbidities that are associated with a poor COVID-19 prognosis.In this letter,we review the literature regarding the association of comorbidities,vitamin D deficiency,and COVID-19. 展开更多
关键词 COVID-19 SARS-CoV-2 comorbidities Vitamin D
下载PDF
Autism medical comorbidities 被引量:4
19
作者 Mohammed Al-Beltagi 《World Journal of Clinical Pediatrics》 2021年第3期15-28,共14页
Medical comorbidities are more common in children with autism spectrum disorders(ASD)than in the general population.Some genetic disorders are more common in children with ASD such as Fragile X syndrome,Down syndrome,... Medical comorbidities are more common in children with autism spectrum disorders(ASD)than in the general population.Some genetic disorders are more common in children with ASD such as Fragile X syndrome,Down syndrome,Duchenne muscular dystrophy,neurofibromatosis type I,and tuberous sclerosis complex.Children with autism are also more prone to a variety of neurological disorders,including epilepsy,macrocephaly,hydrocephalus,cerebral palsy,migraine/headaches,and congenital abnormalities of the nervous system.Besides,sleep disorders are a significant problem in individuals with autism,occurring in about 80%of them.Gastrointestinal(GI)disorders are significantly more common in children with ASD;they occur in 46%to 84%of them.The most common GI problems observed in children with ASD are chronic constipation,chronic diarrhoea,gastroesophageal reflux and/or disease,nausea and/or vomiting,flatulence,chronic bloating,abdominal discomfort,ulcers,colitis,inflammatory bowel disease,food intolerance,and/or failure to thrive.Several categories of inborn-errors of metabolism have been observed in some patients with autism including mitochondrial disorders,disorders of creatine metabolism,selected amino acid disorders,disorders of folate or B12 metabolism,and selected lysosomal storage disorders.A significant proportion of children with ASD have evidence of persistent neuroinflammation,altered inflammatory responses,and immune abnormalities.Anti-brain antibodies may play an important pathoplastic mechanism in autism.Allergic disorders are significantly more common in individuals with ASD from all age groups.They influence the development and severity of symptoms.They could cause problematic behaviours in at least a significant subset of affected children.Therefore,it is important to consider the child with autism as a whole and not overlook possible symptoms as part of autism.The physician should rule out the presence of a medical condition before moving on to other interventions or therapies.Children who enjoy good health have a better chance of learning.This can apply to all children including those with autism. 展开更多
关键词 AUTISM CHILDREN Medical comorbidity EPILEPSY Sleep disorders ALLERGY Gastrointestinal diseases
下载PDF
Health Resource Utilization and Comorbidities in Patients with Mental Disorders: Analysis Based on Health Insurance Claim Data 被引量:1
20
作者 Kana Kazawa Susumu Iwamoto +1 位作者 Md Moshiur Rahman Michiko Moriyama 《Health》 2017年第4期763-777,共15页
The number of patients with mental disorders is increasing all over the world and they have a high prevalence of physical complications. To analyze and compare the cost of mental disorders with the total medical costs... The number of patients with mental disorders is increasing all over the world and they have a high prevalence of physical complications. To analyze and compare the cost of mental disorders with the total medical costs such as mental disorders and physical disorders, we analyzed the cost that patients with mental disorders incurred. We investigated the distribution of medical costs and the characteristics of diseases by using the health insurance claims of people in City A, Japan from March 2013 to February 2014. The subjects had one or more of 4 mental disorders: schizophrenia, alcohol related disorders, bipolar disorder, and depressive episode. As a result, the total number of patients who met inclusion criteria per year was 7403 (6522 outpatients and 881 inpatients). It was revealed that the hospitalization rate of patients with mental disorders increased with age, and many inpatients stayed in hospital for a long time. Also, it was revealed that many patients with mental disorders were in complicated condition with more than one mental or physical disorders and incurred medical costs for these comorbidities. In conclusion, this analysis indicated that many patients with mental disorders switch from attending the outpatient department to hospitalization as they become older. Further, they incurred a lot of medical expenses for complication management. To improve their QOL, comprehensive assessment of their mental/ physical health, self-management education, coordination of services, and support for decision making regarding treatment are necessary. 展开更多
关键词 MENTAL DISORDER Medical COST COMORBIDITY
下载PDF
上一页 1 2 10 下一页 到第
使用帮助 返回顶部